SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a short report from Fuzzy Panda Research alleging misinformation, which the company has vehemently denied, stating strong fundamentals and strategic partnerships with Microsoft and Google. The community is actively discussing the validity of the report, the company's response, and potential trading strategies around upcoming earnings, with some seeing the dip as a buying opportunity before a potential post-earnings rally and others highlighting the risks. Some investors view the recent $200 million capital raise as a strong signal of institutional confidence in the AI-driven retail engagement platform.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending due to a sharp decline following mixed results from a Phase 3 trial, specifically related to a high placebo response in one study, leading to community discussion about the implications for FDA approval. While some investors express concern and compare the situation to other struggling stocks, others view the dip as an overreaction and a buying opportunity, citing the company's strong cash position and ongoing pipeline programs. Discussions revolve around potential for a rebound, possible buyout scenarios, and the influence of institutional ownership.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is experiencing significant volatility, marked by trading halts and a price surge that has captured the attention of day traders. Community discussions revolve around whether this is a pump and dump scenario, with some traders citing the stock's low float and China connection as potential catalysts for rapid price swings. The stock's past reverse splits and the absence of clear news are also fueling speculation and caution among investors.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

CCL is trending as investors react to recent earnings, with mixed sentiment regarding the stock's future performance. While the company beat expectations and raised guidance, the stock price experienced a sell-off, sparking debate about potential overvaluation and profit-taking. Some traders are anticipating a continued climb, while others are hedging their positions or expecting further declines.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending due to recent analyst upgrades and speculation surrounding a potential deal involving TikTok. Community discussions revolve around the stock's rapid ascent and debate whether current valuations are justified. Some traders point to the company's growth in mobile advertising, while others suggest a pullback may be on the horizon.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members highlight its connection to cannabis culture and its potential for growth. Some users are excited about potential upcoming announcements and its association with freedom and community. The coin's contract address is also being shared.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending as the community debates whether the recent pullback presents a buying opportunity or signals further downside, especially when compared to fintech peers. Some traders point to high short interest and technical indicators suggesting a potential short squeeze, while others cite concerns about loan delinquencies and the stock's reaction to broader market trends. Despite varying opinions, many are closely watching for a reversal, potentially fueled by future rate cuts.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Aurora Cannabis is trending as cannabis stocks react to renewed speculation around potential U.S. rescheduling, fueled by comments from political figures. Community discussions highlight the company's medical focus and potential for growth, with some emphasizing its strong financial position compared to its peers. Traders are watching for continued momentum, particularly given the stock's tightly held float and historical price levels.

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts is trending amid speculation of a potential buyout, with discussions focusing on the attractiveness of a 25% premium for shareholders. The community is weighing the implications of sovereign wealth funds acquiring gaming assets, suggesting a shift in the industry's landscape and a possible transition to private ownership. Investors are also reacting to analyst adjustments and evaluating the potential impact on valuation and future game development strategies.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending downwards, with community sentiment reflecting concern and frustration as the stock tests new lows. Investors are actively debating whether the dip presents a buying opportunity or signals deeper issues with the company's growth and valuation, especially when compared to sector peers. Some are optimistic about long-term potential driven by expansion and menu innovation, while others express doubts about the current economic climate impacting consumer spending at fast-casual restaurants.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength?

Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream 

Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum. 

INCY Announces New Late-Stage Data on Skin Disease Drug

Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth

ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.

Barclays has initiated coverage of Incyte (INCY) with an ‘Overweight’ rating and a $90 price target on Friday.The price target implies an over 20% upside to the stock’s closing price on Thursday.&nbsp;Shares of the company traded about 0.4% higher on Friday afternoon at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/INCY">INCY</a> trended in the ‘bullish’ territory, accompanied by ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1332/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_2_26_04_PM_png_30d60d7ced.webp" alt="INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits" width="1332" height="126"><figcaption>INCY's Sentiment Meter and Message Volume as of 2:25 p.m. ET on Aug. 1, 2025 | Source: Stocktwits</figcaption></figure>The firm said that it sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.It believes the pivotal data for Tafasitamab in diffuse large B-cell lymphoma and the mid-stage data for Povorcitinib in chronic spontaneous urticaria patients provide the next legs of growth for Incyte.Earlier this week, Incyte said during its second-quarter earnings that it now expects late-stage data from the study evaluating Tafasitamab as a first-line treatment for diffuse large B-cell lymphoma by the second half of 2025. Incyte is now focusing on its development pipeline as its cancer drug, Jakafi, nears patent expiration.“Continued progress and diversification of our portfolio, including advancements with povorcitinib and mutCALR, are strengthening the foundation for sustainable, long-term growth,” CEO Bill Meury said.Jakafi net revenue came in at $764 million in the second quarter of the year, marking a growth of 8% year-on-year, and accounting for about 63% of the company’s total revenue in the quarter of $1.216 billion, which surpassed Wall Street expectations. &nbsp;For the full year, the company is eyeing revenue of $3 billion to $3.5 billion from Jakafi.Another important drug from the company is its Opzelura cream, used to treat nonsegmental vitiligo, which brought in revenues of $164 million in the second quarter, marking a growth of 35% year-on-year.Overall, for the second quarter, the company reported an adjusted and diluted earnings per share of $1.57, compared to a loss per share of $1.82 reported in the corresponding period of 2024.According to data from Koyfin, 11 of 27 analysts covering the stock rate it ‘Buy’ or higher, while 15 rate it ‘Hold’, and just one rates it a ‘Sell’. The average price target on the stock is $79.87, representing an upside of about 6% from the current price.The stock is up by over 9% this year and by about 17% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pheton-holdings-dismisses-rumors-of-acquisition-by-gilead/chrEENyRdRR">Pheton Holdings Dismisses Rumors Of Acquisition By Gilead, But Retail’s Extremely Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer 

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.

Equity

Barclays sees "value-inflecting" data readouts for the pharmaceutical company in the second half of 2025 and 2026.


Why Incyte (INCY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

INCY
Incyte Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INCY News

INCY Incyte Corp.